Skinvisible Granted US Sunscreen Patent for UVA Absorber
07 Marzo 2012 - 8:05AM
Skinvisible, Inc. (OTCQB:SKVI), a developer of topical and
transdermal formulations using its patented Invisicare technology,
announced today that it has been granted a new patent from the
United States Patent and Trademark Office for "Sunscreen
Composition With Enhanced UVA Absorber Stability and Methods",
Patent Number 8128913. This patent further strengthens the
company's existing intellectual property assets. The patent
provides protection for its sunscreen formulation in the United
States until November 2029.
Skinvisible has developed three sunscreen formulations using
avobenzone; SPF 15, 30 and 50. Although avobenzone is
recognized as the best sun absorber in the US providing UVA
protection, it is known to degrade in sunlight in less than two
hours, resulting in less skin protection over time. Skinvisible's
new formulation with avobenzone has eight hours of photostability,
a unique advantage for everyone who uses sunscreens and works or
plays outdoors. The essential benefits of Skinvisible's
sunscreen formulations are derived from its patented Invisicare
polymer delivery system. This patent adds a distinctive new
category of Invisicare to Skinvisible's portfolio, one which adds
the benefit of photostability to sunscreen formulations and other
future developments.
While the SPF of a sunscreen only provides the level of UVB
protection, a sunscreen with UVA protection protects the skin from
ultraviolet rays that penetrate deeper, go through glass and clouds
and can cause more severe skin damage, wrinkling and even skin
cancer. The FDA has ruled that only sunscreens with a critical
wavelength above 370 nm are allowed to claim they provide UVA
protection. Skinvisible's avobenzone sunscreens surpass this
criterion allowing Skinvisible's sunscreens to meet the new FDA's
2012 guidelines and therefore can be labeled as having "broad
spectrum" UV protection.
"With global sales in suncare reaching $1.7 billion in 2010 and
North America accounting for 21% of that market, the value of this
patented asset is tremendous," stated Mr. Terry Howlett, President
and CEO, Skinvisible. "This patent maximizes the earning potential
of our sunscreen formulations giving them an increased value when
licensed. Skinvisible persists in securing a licensing agreement
for its sunscreen formulations with the objective of maximizing
revenue generation and continuing our mission of creating value for
our company and its shareholders."
About Invisicare
Invisicare is Skinvisible's patented polymer delivery system
that offers life-cycle management and unique enhancements for
topically delivered products. It is a combination of
hydrophilic and hydrophobic polymers that hold active ingredients
on the skin for extended periods of time resisting both wash off
and perspiration. Invisicare can control the release of
actives, reduce irritation and can eliminate some costly
manufacturing processes. It is non-occlusive and allows
for normal skin respiration while protecting against environmental
irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is an R&D company whose primary
business objective is to license its proprietary formulations made
with Invisicare to pharmaceutical, consumer goods and cosmeceutical
companies around the world. Skinvisible receives a combination
of R&D fees, license fees, and ongoing royalties for the life
of the Invisicare patent. Skinvisible has been granted ten
comprehensive patents and has twenty-nine patents
pending. www.skinvisible.com
The Skinvisible, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7744
Forward-Looking Statements: This press release contains
'forward looking' statements within the meaning of Section 21A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks
and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending October 31, 2011).
CONTACT: Corporate Contact:
Doreen McMorran
Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: info@skinvisible.com
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024